USA - engelsk - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg - fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with fosamprenavir plus ritonavir in protease inhibitor-experienced patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fosamprenavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. limited data are available for use of fosamprenavir in pregnancy. fosamprenavir 700 mg twice daily taken with ritonavir 100 mg twice daily should only be considered in pregnant patients who are already on a stable twice-daily regimen of fosamprenavir/ritonavir 700 mg/100 mg prior to pregnancy, and who are virologically suppressed (hiv-1 rna less than 50 copies per ml) (see clinical considerations and data). there are insufficient human data on the use of fosam

USA - engelsk - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with fosamprenavir calcium tabletsplus ritonavir in protease inhibitor-experienced patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fosamprenavir calcium during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data are available for use of fosamprenavir calcium in pregnancy. fosamprenavir calcium 700 mg twice daily taken with ritonavir 100 mg twice daily should only be considered in pregnant patients who are already on a stable twice-daily regimen of fosamprenavir calcium/ritonavir 700 mg/100 mg prior to pregnancy, and who are virologically suppressed (hiv-1 rna less than 50 copies per ml) (see

USA - engelsk - NLM (National Library of Medicine)

viiv healthcare company - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients:     •    lexiva is contraindicated when coadministered with the following drugs:               o     alpha 1-adrenoreceptor antagonist: alfuzosin               o     antiarrhythmics: flecainide (with ritonavir), propafenone (with ritonavir)               o     antimycobacterial: rifampin               o     antipsychotic: lurasidone (with ritonavir), pimozide               o     ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine               o     gi motility agent: cisapride               o     herbal product: st. john’s wort (hypericum perforatum )               o     lipid modifying agents: lomitapide, lovastatin, simvastatin               o     non-nucleoside reverse transcriptase inhibitor: delavirdine     

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fosamprenavir calcium, quantity: 853.2 mg (equivalent: fosamprenavir, qty 700 mg) - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin; iron oxide red - telzir, in combination with low dose ritonavir, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products. in antiretroviral experienced adults telzir in combination with low dose ritonavir has not been shown to be as effective as lopinavir/ritonavir. no comparative studies have been undertaken in children or adolescents.

USA - engelsk - NLM (National Library of Medicine)

state of florida doh central pharmacy - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir calcium 700 mg - lexiva® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients: - the protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that lexiva plus ritonavir and lopinavir plus ritonavir are clinically equivalent [see clinical studies (14.2)] . - once-daily administration of lexiva plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients. lexiva is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome) to any of the components of this product or to amprenavir. - when coadministered with drugs that are highly dependent on cyp3a4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatenin

Canada - engelsk - Health Canada

viiv healthcare ulc - fosamprenavir (fosamprenavir calcium) - tablet - 700mg - fosamprenavir (fosamprenavir calcium) 700mg - hiv protease inhibitors

Canada - engelsk - Health Canada

viiv healthcare ulc - fosamprenavir (fosamprenavir calcium) - suspension - 50mg - fosamprenavir (fosamprenavir calcium) 50mg - hiv protease inhibitors

USA - engelsk - NLM (National Library of Medicine)

avera mckennan hospital - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg

Den europeiske union - slovakisk - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infekcie - antivirotiká na systémové použitie - agenerase, v kombinácii s inými antiretrovirálnej agentov, je indikovaný na liečbu inhibítorov proteináz (pi) zažil hiv-1 infikovaných dospelých a deti vo veku od 4 rokov. agenerase kapsúl, ktoré by mali byť bežne podávané s nízkymi dávkami ritonavirom ako pharmacokinetic enhancer z amprenavir (pozri časť 4. 2 a 4. výber amprenaviru by mal byť založený na individuálnom skúšaní vírusovej rezistencie a histórii liečby pacientov (pozri časť 5). výhody agenerase ritonavir nebola preukázaná v pi jozefa pacientov (pozri časť 5.